FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileKnight Therapeutics Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GUD.TO
Knight Therapeutics Inc. Stock AnalysisComprehensive stock analysis for Knight Therapeutics Inc. (GUD.TO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisGUD.TO
GUD.TO
Knight Therapeutics Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GUD.TO
  1. Home
  2. Stocks
  3. Knight Therapeutics Inc.

Knight Therapeutics Inc.

🇨🇦GUD.TO•TSX

Knight Therapeutics Inc.

🇨🇦GUD.TO•TSX
Market cap
$1.09B
P/E ratio
71.31

Your view on GUD.TO

Mkt Cap
$1.09B
P/E
71.31
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Knight Therapeutics Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Samira Sakhia BCom, CA, CPA, MBA
Headquarters
3400 De Maisonneuve Boulevard West, Montreal, QC, CA
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Samira Sakhia BCom, CA, CPA, MBA
Headquarters
3400 De Maisonneuve Boulevard West, Montreal, QC, CA
Description

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally.

It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.

The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation.

In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections.

Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Knight Therapeutics Inc. from FRC's valuation model, read against the market price. GUD.TO last traded at C$11.14, 71.3× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Knight Therapeutics Inc.. Starting points for Knight Therapeutics Inc.: P/E 71.3, EPS C$0.16, beta 0.05 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Knight Therapeutics Inc.. Trailing twelve-month EPS for Knight Therapeutics Inc. stands at C$0.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Knight Therapeutics Inc.. Knight Therapeutics Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold GUD.TO12 companies
More Drug Manufacturers - Specialty & Generic companies
TickerTypeCompanySectorExchangeMkt cap
BP8.AXBPH Global LtdHealthcareASX—
BSPKBespoke Extracts, Inc.HealthcareOTC$2.8M
BSPMBiostar Pharmaceuticals, Inc.HealthcareOTC$264
BUDZWEED, Inc.HealthcareOTC$4.4M
CAAOFINDVR Brands Inc.HealthcareOTC$3,025
CABRCaring Brands, Inc.HealthcareNASDAQ$6.0M
CAN.AXCann Group LimitedHealthcareASX—
CANNTrees CorporationHealthcareOTC$4.1M
CANQFCanaQuest Medical Corp.HealthcareOTC$6.6M
CATV4Cable TV International, Inc.HealthcareOTC$865,619
CBDDCBD of Denver Inc.HealthcareOTC$980,918
CBDHFHempfusion Wellness Inc.HealthcareOTC$1,635
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Knight Therapeutics Inc.. Coverage tracks Knight Therapeutics Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Knight Therapeutics Inc.

GUD.TO AnalysisGood
Past
5
Growth
5
Health
5
Profit
1
Value
1